Immucell (ICCC) Other financing activities (2010 - 2023)

Immucell's (ICCC) quarterly Other financing activities came in at $1.0 million in Q1 2023, up 50000100.0% on a QoQ basis from -$2.0 in Q4 2022.

Immucell (ICCC) Other financing activities (2010 - 2023) Analysis & Trends

Immucell (ICCC) has 13 years of Other financing activities data on file, last reported at $1.0 million in Q1 2023.

Quarterly Other financing activities changed N/A year-over-year to $1.0 million in Q1 2023, while the trailing twelve-month figure through Dec 2025 was $1.0 million (changed 0.0% YoY) and the FY2025 annual result came in at $3.0, changed N/A from the prior year.
Other financing activities improved to $1.0 million in Q1 2023, from -$2.0 in the prior quarter.
In the past five years, Other financing activities ranged from a high of $8.3 million in Q1 2019 to a low of -$4.2 million in Q4 2021.
A 4-year average of $753522.1 and a median of $78430.0 in 2021 frame the typical range for Other financing activities.
Annual changes were most pronounced in 2019 — Other financing activities surged 199693.94% — and 2022, when it soared 100.0%.
Tracing ICCC's Other financing activities over 4 years: stood at $8.3 million in 2019, then slumped by 150.84% to -$4.2 million in 2021, then soared by 100.0% to -$2.0 in 2022, then surged by 50000100.0% to $1.0 million in 2023.
The last three Other financing activities figures came in at $1.0 million (Q1 2023), -$2.0 (Q4 2022), and -$4.2 million (Q4 2021), per Business Quant data.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	137.11 Bn	129.26 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	84.98 Bn	76.99 Bn	3.93 Bn
3	Argenx Se	64.52 Bn	59.33 Bn	1.37 Bn
4	Moderna	53.23 Bn	48.09 Bn	52.00 Mn
5	BeOne Medicines	41.23 Bn	36.14 Bn	1.53 Bn
6	Alnylam Pharmaceuticals	30.65 Bn	27.34 Bn	992.69 Mn
7	Insmed	27.15 Bn	25.99 Bn	358.27 Mn
8	Royalty Pharma	26.98 Bn	26.14 Bn	-
9	BioNTech SE	26.78 Bn	8.39 Bn	668.28 Mn
10	Immucell	92.01 Mn	83.15 Mn	2.44 Mn

Download Data